MVC is eiaastcdos wthi tginfnice groan ptnstalarn p.ttesani VMC si dteamitsrnt vai uaexls cn,atoct nrago ta,rastpnln or viytlalrce iva ea.nctapl ovaetaiiRtnc fo CMV ccosur in het rn.ieuuossemmspdp
Ognra ntaltnasrp isnttpae are ta an neadicres kirs of VMC unipo.maen
eh saw evnre nigve rovigainccl - i udse atht as a lecu rveo ltspaartnn ircoenetj
hyW owldu isht tno be atecu anasptltnr tejionecr nlidega to R?SDA Teh tcinrineae is alvd,eeet and I ees nay aonrse why ti uwodl eb tevaleed nedybo rentjicoe
via @sammyj98 via UpToDate:
Universal prophylaxis with valganciclovir or ganciclovir is typically given to patients at risk for cytomegalovirus (CMV) reactivation (eg, seropositive recipients and those with seropositive donors). The duration of therapy often depends on the type of organ transplanted, the risk status of the patient, and individual institutional practice. Some transplant centers prefer to use a pre-emptive approach (eg, routine CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations.
submitted by ∗amorah(115)
It can be re-accessed by making a purchase.
Purchase your membership here
$279$49Ferev -&;gt rleu uot lfte rarceliuvtn iarfelu PX -SMMT prlhxosyiap ;-tg& reul uot Pestuysoincm injr dieKeiocyv atlrsantnp but on /RBCCWB in riuen -> rleu out atrnnplats irntoeejc
vainegL MVC dna atcyilpa cacoytmierumb sa teh arenimgni two tpin.oso CMV is orme likyle ni a ttapransnl ipt.nate
$279$49